Aspirin Inhibition of ÃÂ±-Granules Release is Associated with Sirt1/AMPK and PI3K/Akt Pathway in Thrombin-Activated Platelets
- *Corresponding Author:
- Ruomei Qi
Dahua Road, Dongcheng District, Beijing, 100730, China
E-mail: [email protected]
Received date: June 07, 2016; Accepted date: June 27, 2016; Published date: July 04, 2016
Citation: Sun J, Zhang M, Liu X, Zhao X, Jiang Y, et al. (2016) Aspirin Inhibition of α-Granules Release is Associated with Sirt1/AMPK and PI3K/Akt Pathway in Thrombin-Activated Platelets. Cardiovasc Ther 1:111.
Copyright: © 2016 Sun J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: To investigated the effect of aspirin on inhibition of platelet α-granules release in thrombin-activated platelets.
Methods: Human platelets were used in the present study. Protein expression and phosphorylation was determined by Western blot. The secreted CD40L and PF4 from platelets were detected by ELISA.
Results: Aspirin reduced CD40L and PF4 expression in thrombin-activated platelets. Sirt1 expression and AMPK phosphorylation was decreased by 24.4% and by 19.2% in thrombin-activated platelets. In contrast, aspirin dosedependently recovered Sirt1 expression and AMPK phosphorylation. EX527 (a Sirt1 inhibitor) treatment resulted in an increase in CD40L and PF4 expression. The combination of EX527 and aspirin weakened the inhibitory effect of aspirin on platelet aggregation, the expression of CD40L and PF4. Moreover, aspirin abolished the phosphorylation of Akt inthrombin-activated platelets. Aspirin has a synergistic action with LY294002 (an Akt inhibitor) on inhibition of thrombin-induced CD40L and PF4 expression.
Conclusions: Our results provide new evidence that the aspirin inhibiting platelet α-granules release not only is associated with suppressing Akt activation but also linked to activating Sirt1/AMPK pathway in thrombin-activated platelets